Tech view: Nifty Pharma is headed for a strong rally; watch for 9350 levels

In the last five sessions, the index has been hovering at 200-days moving average (DMA) located around 9230, as per daily chart. A major trigger for a bigger run stays at 9350 levels

Tech view: Nifty Pharma is headed for a strong rally; watch for 9350 levels
Prices slashed by up to 87 per cent. The average expenditure on cancer drugs is 2.5 times that of other medicines
Avdhut Bagkar Mumbai
2 min read Last Updated : Mar 19 2019 | 11:23 AM IST
NIFTYPHARMA: The bigger picture on the chart reveals a consolidation in the range of 9050 – 8550 levels. The current price of 9200 clearly denotes breakout with immediate target levels of 9550 and 9700 levels. The technical indicator MACD (moving average convergence and divergence), is seeing a positive crossover. The rise above zero line further supports the breakout move.

In the last five sessions, the index has been hovering at 200-days moving average (DMA) located around 9230, as per daily chart. A major trigger for a bigger run stays at 9350 levels. Any move above this can see a strong rally.


The immediate support is at 8911 levels, its 50 DMA. The same will converge with 100DMA, currently placed at 8992 if the index crosses 9350 levels. If so, then every correction will eventually witness buying momentum at respective moving averages.

Divis's Laboratories (Divislab) has risen 70 per cent in the last nine months. Though the stock has not been in the limelight off-late, Divi's Labs is the only stock that has hit new highs every quarter. The stock has actually tripled, delivering 300 per cent return in less than two years.

Technically, stock making 52-weeks high has always witnessed addition in volumes till technical indicators do not make negative crossovers. Immediate support stalls at Rs 1600 with trend heading towards Rs 1850 levels.

Aurobindo Pharma (Auropharma), on the other hand, is just Rs 35 shy of lifetime high Rs 826. It has gained nearly 40 per cent in the last nine months. The daily chart shows convergence of 50 DMA with 100 DMA indicating trend towards Rs 850 and Rs 880. The support comes at 740 levels. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story